Abstract
Purpose. To synthesize and evaluate various novel aminoacyloxyalkyl esters of naproxen (3a-i) and naproxenoxyalkyl diesters of glutamic and aspartic acids (3j-m) as potential dermal prodrugs of naproxen.
Methods. The prodrugs 3a-m were synthesized, and their aqueous solubilities, lipophilicities and hydrolysis rates were determined in a buffered solution and in human serum. The permeation of selected prodrugs across excised postmortem human skin was studied in vitro.
Results. The aminoacyloxyalkyl prodrugs showed higher aqueous solubilities and similar lipid solubilities, in terms of octanol-buffer partition coefficients (log Papp) at pH 5.0, when compared with naproxen. At pH 7.4 the prodrugs were significantly more lipophilic than naproxen. Prodrugs3a-i showed moderate chemical stability in aqueous solutions at pH 5.0 and were rapidly converted to naproxen in human serum (t1/2 = 4−19 min). The selected aminoacyloxyalkyl prodrugs possessed a higher flux across the skin than naproxen, with a maximum enhancement of 3-fold compared to naproxen. Prodrugs 3j-mshowed poor aqueous solubility and permeation across the skin.
Conclusions. Combinations of adequate aqueous solubility and lipophilicity of naproxen aminoacyloxyalkyl prodrugs having fast rates of enzymatic hydrolysis resulted in improved dermal delivery of naproxen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
H. Suh, H. W. Jun, M. T. Dzimianski, and G. W. Lu. Pharmacokinetic and local tissue disposition studies of naproxen following topical and systemic administration in dogs and rats. Biopharm. Drug Disp. 18:623-633 (1997).
S. C. McNeill, R. O. Potts, and M. L. Francoeur. Local enhanced topical delivery (LETD) of drugs: Does it truly exist? Pharm. Res. 9:1422-1427 (1992).
P. Singh and M. S. Roberts. Skin permeability and local tissue concentrations of nonsteroidal anti-Inflammatory drugs after topical application. J. Pharmacol. Exp. Ther. 268:144-151 (1994).
R. N. Brogden, R. C. Heel, T. M. Speight, and G. S. Avery. Naproxen up to date: A review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states. Drugs 18:241-277 (1979).
T. Yano, A. Nakagawa, M. Tsuji, and K. Noda. Skin permeability of various non-steroidal anti-Inflammatory drugs in man. Life Sci. 39:1043-1050 (1986).
F. A. van den Ouweland, P. C. Eenhoorn, Y. Tan, and F. W. J. Gribnau. Transcutaneous absorption of naproxen gel. Eur. J. Clin. Pharmacol. 36:209-211 (1989).
G. B. Kasting, R. L. Smith, and B. D. Anderson. Prodrugs for dermal delivery: Solubility, molecular size, and functional group effects. In K. B. Sloan (ed.), Prodrugs, Topical and Ocular Drug Delivery, Marcel Dekker, inc., New York, 1992, pp 117-161.
L. G. Mueller. Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation. US Patent 4,912, 248 (1990).
H. Weber, K. Meyer-Trümpener, and B.C. Lippold. Ester des naproxens als potentielle prodrugs zur hautpenetration. 2. mitt.: Penetrationseigenschaften an exzidierter mäusehaut. Arch. Pharm. (Weinheim) 327:681-686 (1994).
F. P. Bonina, L. Montenegro, and F. Guerrera. Naproxen 1-alkylazacycloalkan-2-one esters as dermal prodrugs: In vitro evaluation. Int. J. Pharm. 100:99-105 (1993).
J. Rautio, H. Taipale, J. Gynther, J. Vepsäläinen, T. Nevalainen, and T. Järvinen. In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen. J. Pharm. Sci. 87:1622-1628 (1998).
E. J. F. Franssen, J. Koiter, C. A. M. Kuipers, A. P. Bruins, F. Moolenaar, D. de Zeeuw, W. H. Kruizinga, R. M. Kellogg, and D. K. F. Meijer. Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism on renal cortex homogenates and lysosomal lysates. J. Med. Chem. 35:1246-1259 (1992).
T. Järvinen, M. Poikolainen, P. Suhonen, J. Vepsäläinen, S. Alaranta, and A. Urtti. Comparison of enzymatic hydrolysis of pilocarpine prodrugs in human plasma, rabbit cornea, and butyrylcholinesterase solutions. J. Pharm. Sci. 84:656-660 (1995).
K. B. Sloan, J. J. Getz, H. D. Beall, and R. J. Prankerd. Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkylaminocarbonyl-5-FU prodrugs: Physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm. 93:27-36 (1993).
F. P. Bonina, L. Montenegro, P. De Caprariis, F. Palagiano, G. Trapani, and G. Liso. In vitro and in vivo evaluation of polyoxyethylene indomethacin esters as dermal prodrugs. J. Contr. Rel. 34:223-232 (1995).
S. Y. Chang, S. B. Park, J. H. Jung, S. I. Shon, and H. J. Yoon. Ibuprofen heterocyclic esters as dermal prodrugs in vitro evaluation. S. T. P. Pharma Sci. 7:315-319 (1997).
H. Bundgaard, N. Mork, and A. Hoelgaard. Enhanced delivery of nalidixic acid through human skin via acyloxymethyl ester prodrugs. Int. J. Pharm. 55:91-97 (1989a).
M. Johansen, B. Mollgaard, P. K. Wotton, C. Larsen, and A. Hoelgaard. In vitro evaluation of dermal prodrug delivery—transport and bioconversion of a series of aliphatic esters of metronidazole. Int. J. Pharm. 32:199-206 (1986).
H. Bundgaard. The double prodrug concept and its applications. Adv. Drug Del. Rev. 3:39-65 (1989b).
K. B. Sloan. Prodrugs for dermal delivery. Adv. Drug Del. Rev. 3:67-101 (1989).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rautio, J., Nevalainen, T., Taipale, H. et al. Synthesis and In Vitro Evaluation of Aminoacyloxyalkyl Esters of 2-(6-methoxy-2-naphthyl)propionic Acid as Novel Naproxen Prodrugs for Dermal Drug Delivery. Pharm Res 16, 1172–1178 (1999). https://doi.org/10.1023/A:1018981010047
Issue Date:
DOI: https://doi.org/10.1023/A:1018981010047